logo

CTMX

CytomX Therapeutics·NASDAQ
--
--(--)
--
--(--)
5.75 / 10
Netural

Analyst consensus is overwhelmingly bullish: 80% Buy and 20% Strong Buy ratings from four active analysts, with a historical weighted rating of 4.17. Fund flow analysis shows a 7.33/10 score, with positive Small and Large inflow trends despite overall negative flow. This combination of strong analyst conviction and robust money inflows supports the technical strength, but investors should remain mindful of the stock's fundamental weaknesses.

FundamentalSentiment(5.75)Technical
Fund Flow Rating
Analyst RatingBuy

Wall Street Opinions

Buy

Strong Buy

20%

Buy

80%

Hold

0%

Sell

0%

Strong Sell

0%

Date2026-02-04
InstitutionBarclays
Times predicted4
Historical Win Rate75.0%
Is money flowing into or out of CTMX?
  • CTMX holds a Bearish analyst rating, with 80% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 5.75/10 (Netural).